D de Lucena, BS Fernandes, M Berk, S Dodd, DW Medeiros, M Pedrini, M Kunz, FA Gomes, LF Giglio, MI Lobato, PS Belmonte-de-Abreu and CS Gama,
The Journal of clinical psychiatry, Oct 2009
Glutamate deregulation may be involved in the neuropathology of schizophrenia, mainly through N-methyl-d-aspartate (NMDA) receptor dysfunction. Memantine, a drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease, acts as a weak nonselective NMDA receptor antagonist. The aim of this study was to examine the efficacy of memantine as an adjunctive treatment to clozapine in patients with refractory schizophrenia.